AVDL
Avadel PharmaceuticalsAVDL
AVDL
About: Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.
Employees: 188
0
Funds holding %
of 7,312 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
65% more first-time investments, than exits
New positions opened: 43 | Existing positions closed: 26
29% more repeat investments, than reductions
Existing positions increased: 58 | Existing positions reduced: 45
9% more funds holding
Funds holding: 157 [Q4 2024] → 171 (+14) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 7 [Q4 2024] → 7 (+0) [Q1 2025]
1.97% less ownership
Funds ownership: 82.28% [Q4 2024] → 80.31% (-1.97%) [Q1 2025]
27% less capital invested
Capital invested by funds: $833M [Q4 2024] → $611M (-$222M) [Q1 2025]
44% less call options, than puts
Call options by funds: $2.25M | Put options by funds: $3.99M
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$19
98%
upside
Avg. target
$19
98%
upside
High target
$19
98%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Needham Ami Fadia | 98%upside $19 | Buy Reiterated | 8 May 2025 |
Financial journalist opinion
Based on 8 articles about AVDL published over the past 30 days
Negative
Reuters
1 week ago
ASL pushes for board shakeup at Avadel over handling of sleep drug rollout
ASL Strategic Value Fund on Monday urged shareholders of Avadel Pharmaceuticals to replace its board, citing mismanagement in the rollout of the drugmaker's flagship sleep disorder drug Lumryz since its launch two years ago.
Neutral
GlobeNewsWire
1 week ago
Avadel Pharmaceuticals Announces Unanimous Appeals Court Decision Upholding FDA Approval of LUMRYZ in Narcolepsy in Administrative Procedure Act Litigation
DUBLIN, June 30, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced that, on Friday, June 27, 2025, the U.S. Court of Appeals for the District of Columbia Circuit (the “Appeals Court”) affirmed a prior decision of the U.S. District Court for the District of Columbia (the “District Court”) in favor of the U.S. Food and Drug Administration (“FDA”) in a suit brought by Jazz Pharmaceuticals Inc. (“Jazz”) regarding the FDA's approval of LUMRYZTM, the first and only once-at-bedtime oxybate treatment for cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy.
Neutral
Business Wire
1 week ago
ASL Strategic Value Fund Issues Open Letter to Avadel Shareholders
GREENWICH, Conn. & CHESTERFIELD, Mo.--(BUSINESS WIRE)--ASL Strategic Value Fund, LP (together with its affiliates, “ASL Strategic Value Fund” or “we”), a significant shareholder of Avadel Pharmaceuticals plc (NASDAQ: AVDL) (“Avadel” or the “Company”), today issued an open letter calling on Avadel's shareholders to vote AGAINST all of the Company's director nominees up for election at the 2025 annual general meeting of shareholders scheduled for July 29, 2025 (the “Annual Meeting”). The full tex.
Negative
Reuters
1 week ago
ASL Strategic Value Fund targets Avadel board over Lumryz drug mismanagement, WSJ reports
ASL Strategic Value Fund plans to push shareholders of drugmaker Avadel Pharmaceuticals to vote to remove the company's board, citing mismanagement in the launch of its flagship sleep disorder drug, the Wall Street Journal reported on Sunday.
Negative
WSJ
1 week ago
An investor in the narcolepsy drugmaker Avadel Pharmaceuticals plans to call for shareholders to vote out the company's entire board of directors, ratcheting up pressure
ASL Strategic Value Fund wants the narcolepsy drugmaker to retain investment bankers and consider a sale.
Neutral
GlobeNewsWire
3 weeks ago
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
DUBLIN, June 16, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced that the Compensation Committee of Avadel's Board of Directors approved the grant of non-statutory options to two new employees to purchase 9,600 ordinary shares under Avadel's 2021 Inducement Plan. In addition, effective as of May 13, 2025, the Compensation Committee of Avadel's Board of Directors approved a grant of non-statutory options to Susan Rodriguez, Avadel's newly appointed Chief Operating Officer, to purchase 300,000 ordinary shares under Avadel's 2021 Inducement Plan.
Positive
Zacks Investment Research
3 weeks ago
Wall Street Analysts See an 81.61% Upside in Avadel (AVDL): Can the Stock Really Move This High?
The consensus price target hints at an 81.6% upside potential for Avadel (AVDL). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Positive
Zacks Investment Research
4 weeks ago
Surging Earnings Estimates Signal Upside for Avadel (AVDL) Stock
Avadel (AVDL) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Neutral
GlobeNewsWire
1 month ago
Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia
DUBLIN, June 05, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that LUMRYZTM has been granted Orphan Drug Designation (ODD) from the U.S. Food & Drug Administration (FDA) for the treatment of Idiopathic Hypersomnia (IH). Specifically, ODD was granted based on the plausible hypothesis that LUMRYZ may be clinically superior to the same drug(s) already approved for the same indication, because LUMRYZ may provide a major contribution to patient care due to its once-nightly dosing for patients with IH, a chronic sleep disorder that requires potentially lifelong treatment.
Neutral
GlobeNewsWire
1 month ago
Avadel Pharmaceuticals to Present New Data on LUMRYZ™ (sodium oxybate) For Extended-Release Oral Suspension at SLEEP 2025
– 14 abstracts accepted, including four oral presentations – – Interim analysis of real-world REFRESH study demonstrated clinically significant efficacy and improvement of EDS for patients who switched from twice-nightly oxybate to once-at-bedtime LUMRYZ – – Data reflecting the therapeutic results of LUMRYZ treatment in people with narcolepsy across clinical as well as real-world settings will be presented – DUBLIN, Ireland, May 29, 2025 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced that new data supporting the use of LUMRYZ as a narcolepsy treatment and additional data to better understand the real-life experience of people living with narcolepsy will be presented in four oral presentations and 14 posters at SLEEP 2025, the 39th Annual Meeting of the Associated Professional Sleep Societies (APSS), taking place June 8-11, 2025 in Seattle. “Post-hoc analysis of the pivotal Phase 3 REST-ON clinical trial, restricted to those study participants with the most severe sleepiness at baseline as measured both objectively and subjectively, showed LUMRYZ participants with a median Epworth Sleepiness Scale (ESS) score at Week 13 that was improved to the range at or below that considered normal.
Charts implemented using Lightweight Charts™